Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 2
2007 1
2008 2
2009 3
2010 3
2011 4
2012 8
2013 1
2015 4
2016 2
2017 6
2018 4
2019 3
2020 6
2021 6
2022 7
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. Hammond SM, et al. Among authors: goyenvalle at. EMBO Mol Med. 2021 Apr 9;13(4):e13243. doi: 10.15252/emmm.202013243. Epub 2021 Apr 6. EMBO Mol Med. 2021. PMID: 33821570 Free PMC article. Review.
Exon-skipping advances for Duchenne muscular dystrophy.
Echevarría L, Aupy P, Goyenvalle A. Echevarría L, et al. Among authors: goyenvalle a. Hum Mol Genet. 2018 Aug 1;27(R2):R163-R172. doi: 10.1093/hmg/ddy171. Hum Mol Genet. 2018. PMID: 29771317 Review.
Viral Vector-Mediated Antisense Therapy for Genetic Diseases.
Imbert M, Dias-Florencio G, Goyenvalle A. Imbert M, et al. Among authors: goyenvalle a. Genes (Basel). 2017 Jan 26;8(2):51. doi: 10.3390/genes8020051. Genes (Basel). 2017. PMID: 28134780 Free PMC article. Review.
Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle.
Morin A, Stantzou A, Petrova ON, Hildyard J, Tensorer T, Matouk M, Petkova MV, Richard I, Manoliu T, Goyenvalle A, Falcone S, Schuelke M, Laplace-Builhé C, Piercy RJ, Garcia L, Amthor H. Morin A, et al. Among authors: goyenvalle a. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2206324120. doi: 10.1073/pnas.2206324120. Epub 2023 Jan 3. Proc Natl Acad Sci U S A. 2023. PMID: 36595689 Free PMC article.
Therapeutic approaches to muscular dystrophy.
Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Goyenvalle A, et al. Hum Mol Genet. 2011 Apr 15;20(R1):R69-78. doi: 10.1093/hmg/ddr105. Epub 2011 Mar 24. Hum Mol Genet. 2011. PMID: 21436158 Free PMC article. Review.
Delivery is key: lessons learnt from developing splice-switching antisense therapies.
Godfrey C, Desviat LR, Smedsrød B, Piétri-Rouxel F, Denti MA, Disterer P, Lorain S, Nogales-Gadea G, Sardone V, Anwar R, El Andaloussi S, Lehto T, Khoo B, Brolin C, van Roon-Mom WM, Goyenvalle A, Aartsma-Rus A, Arechavala-Gomeza V. Godfrey C, et al. Among authors: goyenvalle a. EMBO Mol Med. 2017 May;9(5):545-557. doi: 10.15252/emmm.201607199. EMBO Mol Med. 2017. PMID: 28289078 Free PMC article. Review.
RNA-targeted drugs for neuromuscular diseases.
Ferlini A, Goyenvalle A, Muntoni F. Ferlini A, et al. Among authors: goyenvalle a. Science. 2021 Jan 1;371(6524):29-31. doi: 10.1126/science.aba4515. Science. 2021. PMID: 33384365 Free article. No abstract available.
69 results